SYRS Nasdaq

Syros Pharmaceuticals, Inc.

SYRS | $4.76 -6.85% -7.35% 120K

(0.0% 1d) (-19.3% 1m) (95.8% 1y) (0.0% 2d) (0.0% 3d) (-4.5% 7d) (-56.13% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 29,990,518
http://www.syros.com
Sec Filling | Patents | 83 employees

(US) Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

cancer

add to watch list Paper trade email alert is off

Press-releases

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 10.13% | O: 2.16% H: 23.21% C: 16.03%
fda treatment designation for aml

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| -18.24% | O: -4.8% H: 3.7% C: -1.85%
year update financial results

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| -18.5% | O: -0.32% H: 3.84% C: 2.4%
trial

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| -17.98% | O: 0.32% H: 2.08% C: 1.28%
report year financial results

Syros to Participate in TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27 (Crawled : 13:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| -31.78% | O: 1.07% H: 5.15% C: -3.04%
conference health care

Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Published: 2023-12-19 (Crawled : 14:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 18.84% | O: 2.56% H: 28.34% C: 27.66%
offering

Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Published: 2023-12-06 (Crawled : 15:30) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 81.21% | O: 2.13% H: 61.11% C: 39.58%
trial

Syros to Participate in Upcoming Investor Conferences - November 21, 2023
Published: 2023-11-21 (Crawled : 19:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 78.05% | O: -2.09% H: 6.05% C: 3.2%

Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-11-14 (Crawled : 15:30) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 89.96% | O: -5.2% H: 6.67% C: 6.67%
update financial results

Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
SYRS | $4.76 -6.85% -7.35% 120K

Health Technology

| 82.5% | O: 2.14% H: 4.55% C: 3.15%
report financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-040302	4	2024-04-02	2024-03-31	Sell	M	13333	26667
0000950170-24-040302	4	2024-04-02	2024-03-31	Sell	M	2000	4000
0000950170-24-040302	4	2024-04-02	2024-04-02	Sell	S	150	10451
0000950170-24-040302	4	2024-04-02	2024-04-01	Sell	F	4732	10601
0000950170-24-040302	4	2024-04-02	2024-03-31	Buy	M	13333	15333
0000950170-24-040302	4	2024-04-02	2024-03-31	Buy	M	2000	2000
0000950170-24-040297	4	2024-04-02	2024-03-27	Sell	M	22500	0
0000950170-24-040297	4	2024-04-02	2024-03-28	Sell	F	7046	39757
0000950170-24-040297	4	2024-04-02	2024-03-27	Buy	M	22500	46803